Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The American Hospital Association is asking antitrust regulators to rethink how they evaluate hospital mergers — going beyond just commercial insurance prices. Backed by a Kaufman Hall report, the AHA argues that patient mix, financial stability, and service-line competition deserve equal weight. Nearly 60% of acute care hospital patient days involve Medicare or Medicaid patients, whose prices regulators don't control anyway.
The American Hospital Association (AHA) is pushing back on how antitrust regulators assess hospital mergers, arguing the current framework is too narrow. In a new report commissioned from healthcare advisory firm Kaufman Hall, the AHA urges agencies to weigh factors like patient population composition, the financial fallout of blocked deals, and service-line competition — not just the effect on commercial insurance prices.
The core argument: nearly 60% of acute care hospital patient days involve Medicare and Medicaid patients, whose prices are government-set and wouldn't change post-merger. Blocking a deal to protect commercial payer rates, the AHA says, ignores what happens to the majority of patients who depend on those hospitals for access to care.
Kaufman Hall's data also shows that hospitals targeted in blocked mergers often serve more vulnerable, government-insured communities — and that failed deals can accelerate financial decline, with acquirees seeing a median 50% drop in operating profit margin within a year.
By the Numbers:
Why it matters: The AHA's push comes as regulators and researchers broadly link hospital consolidation to higher costs — making this a high-stakes debate over how antitrust policy balances market competition with patient access and hospital financial viability.
